Titre : Inhibition nerveuse

Inhibition nerveuse : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibition nerveuse : Questions médicales les plus fréquentes", "headline": "Inhibition nerveuse : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibition nerveuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-04", "dateModified": "2025-03-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibition nerveuse" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phénomènes physiologiques du système nerveux", "url": "https://questionsmedicales.fr/mesh/D009424", "about": { "@type": "MedicalCondition", "name": "Phénomènes physiologiques du système nerveux", "code": { "@type": "MedicalCode", "code": "D009424", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibition nerveuse", "alternateName": "Neural Inhibition", "code": { "@type": "MedicalCode", "code": "D009433", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Chiang-Shan R Li", "url": "https://questionsmedicales.fr/author/Chiang-Shan%20R%20Li", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, USA." } }, { "@type": "Person", "name": "Thang M Le", "url": "https://questionsmedicales.fr/author/Thang%20M%20Le", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: thang.le@yale.edu." } }, { "@type": "Person", "name": "Barry R Komisaruk", "url": "https://questionsmedicales.fr/author/Barry%20R%20Komisaruk", "affiliation": { "@type": "Organization", "name": "Department Psychology, Rutgers University, Newark, NJ, USA. Electronic address: brk@psychology.rutgers.edu." } }, { "@type": "Person", "name": "Maria Cruz Rodriguez Del Cerro", "url": "https://questionsmedicales.fr/author/Maria%20Cruz%20Rodriguez%20Del%20Cerro", "affiliation": { "@type": "Organization", "name": "Department Psychobiology, Universidad Nacional de Educación a Distancia, Madrid, Spain." } }, { "@type": "Person", "name": "Sheng Zhang", "url": "https://questionsmedicales.fr/author/Sheng%20Zhang", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452169", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-13934-1" } }, { "@type": "ScholarlyArticle", "name": "Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.", "datePublished": "2024-04-29", "url": "https://questionsmedicales.fr/article/38756630", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/jgo-24-218" } }, { "@type": "ScholarlyArticle", "name": "Intensity-modulated proton and carbon-ion radiotherapy using fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.", "datePublished": "2023-12-08", "url": "https://questionsmedicales.fr/article/38064747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1088/1361-6560/ad13d1" } }, { "@type": "ScholarlyArticle", "name": "A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.", "datePublished": "2023-06-02", "url": "https://questionsmedicales.fr/article/37271306", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.diabet.2023.101455" } }, { "@type": "ScholarlyArticle", "name": "Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37467889", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jprot.2023.104971" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques de l'appareil locomoteur et du système nerveux", "item": "https://questionsmedicales.fr/mesh/D055687" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes physiologiques du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009424" }, { "@type": "ListItem", "position": 4, "name": "Inhibition nerveuse", "item": "https://questionsmedicales.fr/mesh/D009433" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibition nerveuse - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibition nerveuse", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibition nerveuse", "description": "Comment diagnostiquer l'inhibition nerveuse ?\nQuels tests sont utilisés pour l'inhibition nerveuse ?\nQuels signes cliniques indiquent une inhibition nerveuse ?\nL'imagerie est-elle utile pour l'inhibition nerveuse ?\nPeut-on mesurer l'inhibition nerveuse ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibition nerveuse", "description": "Quels sont les symptômes de l'inhibition nerveuse ?\nL'inhibition nerveuse cause-t-elle des spasmes musculaires ?\nY a-t-il des symptômes cognitifs associés ?\nComment l'inhibition nerveuse affecte-t-elle la motricité ?\nL'inhibition nerveuse peut-elle causer des troubles sensoriels ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibition nerveuse", "description": "Comment prévenir l'inhibition nerveuse ?\nL'exercice régulier aide-t-il à prévenir l'inhibition nerveuse ?\nLes pauses au travail sont-elles importantes ?\nUne alimentation équilibrée peut-elle aider ?\nLe stress influence-t-il l'inhibition nerveuse ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibition nerveuse", "description": "Quels traitements existent pour l'inhibition nerveuse ?\nLes médicaments peuvent-ils aider l'inhibition nerveuse ?\nLa physiothérapie est-elle efficace ?\nQuand la chirurgie est-elle envisagée ?\nY a-t-il des thérapies alternatives pour l'inhibition nerveuse ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibition nerveuse", "description": "Quelles complications peuvent survenir ?\nL'inhibition nerveuse peut-elle entraîner des handicaps ?\nY a-t-il des risques de dépression associés ?\nDes troubles de la coordination peuvent-ils survenir ?\nL'inhibition nerveuse peut-elle affecter la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibition nerveuse", "description": "Quels sont les facteurs de risque de l'inhibition nerveuse ?\nLe diabète est-il un facteur de risque ?\nLe surpoids influence-t-il l'inhibition nerveuse ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Probability&page=275#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'inhibition nerveuse ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens neurologiques et des tests électrophysiologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'inhibition nerveuse ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'EMG et les potentiels évoqués pour évaluer la conduction nerveuse." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une inhibition nerveuse ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme la faiblesse musculaire et des réflexes diminués peuvent indiquer une inhibition." } }, { "@type": "Question", "name": "L'imagerie est-elle utile pour l'inhibition nerveuse ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IRM peut aider à visualiser des anomalies structurelles affectant les nerfs." } }, { "@type": "Question", "name": "Peut-on mesurer l'inhibition nerveuse ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques mesurent l'activité électrique des neurones inhibés." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'inhibition nerveuse ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, engourdissement, et perte de coordination." } }, { "@type": "Question", "name": "L'inhibition nerveuse cause-t-elle des spasmes musculaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des spasmes musculaires en raison d'une activité nerveuse altérée." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cognitifs associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la concentration et de la mémoire peuvent survenir avec l'inhibition nerveuse." } }, { "@type": "Question", "name": "Comment l'inhibition nerveuse affecte-t-elle la motricité ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer une faiblesse musculaire et des difficultés de mouvement." } }, { "@type": "Question", "name": "L'inhibition nerveuse peut-elle causer des troubles sensoriels ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des sensations anormales comme des picotements peuvent se manifester." } }, { "@type": "Question", "name": "Comment prévenir l'inhibition nerveuse ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une bonne posture et éviter les mouvements répétitifs peut aider à prévenir." } }, { "@type": "Question", "name": "L'exercice régulier aide-t-il à prévenir l'inhibition nerveuse ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice renforce les muscles et améliore la circulation nerveuse." } }, { "@type": "Question", "name": "Les pauses au travail sont-elles importantes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, faire des pauses régulières réduit le risque de stress nerveux et de blessures." } }, { "@type": "Question", "name": "Une alimentation équilibrée peut-elle aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en nutriments soutient la santé nerveuse." } }, { "@type": "Question", "name": "Le stress influence-t-il l'inhibition nerveuse ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les symptômes d'inhibition nerveuse." } }, { "@type": "Question", "name": "Quels traitements existent pour l'inhibition nerveuse ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la physiothérapie, les médicaments et parfois la chirurgie." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider l'inhibition nerveuse ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des analgésiques et des anti-inflammatoires peuvent soulager les symptômes." } }, { "@type": "Question", "name": "La physiothérapie est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à renforcer les muscles et améliorer la coordination." } }, { "@type": "Question", "name": "Quand la chirurgie est-elle envisagée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est envisagée si les traitements conservateurs échouent ou en cas de compression nerveuse." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour l'inhibition nerveuse ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies comme l'acupuncture peuvent être bénéfiques pour certains patients." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des douleurs chroniques et des troubles de la mobilité." } }, { "@type": "Question", "name": "L'inhibition nerveuse peut-elle entraîner des handicaps ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des handicaps fonctionnels peuvent résulter d'une inhibition nerveuse sévère." } }, { "@type": "Question", "name": "Y a-t-il des risques de dépression associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la douleur chronique liée à l'inhibition nerveuse peut contribuer à la dépression." } }, { "@type": "Question", "name": "Des troubles de la coordination peuvent-ils survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inhibition nerveuse peut affecter la coordination et l'équilibre." } }, { "@type": "Question", "name": "L'inhibition nerveuse peut-elle affecter la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut réduire la qualité de vie en limitant les activités quotidiennes." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'inhibition nerveuse ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les blessures, et certaines maladies chroniques." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut endommager les nerfs et augmenter le risque d'inhibition nerveuse." } }, { "@type": "Question", "name": "Le surpoids influence-t-il l'inhibition nerveuse ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le surpoids peut exercer une pression sur les nerfs, augmentant le risque." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles nerveux peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut nuire à la circulation sanguine et affecter les nerfs." } } ] } ] }

Sources (2758 au total)

Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.

There is a group of hypopharyngeal squamous cell carcinoma (HPSCC) patients for whom larynx-preserving open partial pharyngectomy (PP) and radiotherapy/chemoradiotherapy (RT/CRT) are indicated. We aim... This study evaluated HPSCC patients who were initially treated by PP or RT/CRT at our institution between January 2007 and October 2019. Overall survival (OS), disease-specific survival (DSS), larynge... Overall, 198 patients were enrolled; 63 and 135 underwent PP and RT/CRT, respectively. IPTW-adjusted 5-year OS, DSS, LFS, and LRFS rates in the PP and RT/CRT groups were 84.3% and 61.9% (p = 0.019), 8... Despite the risk of bias related to unadjusted factors, our results suggest that PP is associated with significantly better OS and LFS compared with RT/CRT for HPSCC....

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

While surufatinib, sunitinib, and everolimus have shown efficacy for advanced neuroendocrine neoplasms (NENs) in randomized controlled trials (RCTs), direct comparisons in a real-world setting remain ... A retrospective, observational study was conducted at Fudan University Shanghai Cancer Center, including patients with advanced NENs treated with surufatinib, sunitinib, or everolimus between July 202... The study enrolled 123, 56, and 68 locally advanced or metastatic NEN patients treated with surufatinib, sunitinib, and everolimus, respectively. Before adjusting for confounding factors, surufatinib ... In a real-world Chinese cohort, surufatinib significantly outperformed sunitinib and everolimus in prolonging PFS among advanced NEN patients, with identifiable clinical features impacting survival, a...

A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.

The classical glycosylated hemoglobin A1c threshold of 6.5% is an insensitive screening test for cystic fibrosis-related diabetes (CFRD). We sought to identify CF-specific A1C thresholds associated wi... We studied the cross sectional and longitudinal associations between A1c, BMI, and FEV1 in 2 cohorts of 223 children (followed for up to 8 years) and 289 adults (followed for a mean of 7.5 ± 4.3 years... For the onset of OGTT-defined CFRD optimal A1c threshold was 5.9% in adults (sensitivity: 67% and specificity: 71%) and 5.7% for children (sensitivity: 60% and specificity: 47%). Kaplan-Meier analysis... An A1C above 6% may be associated with a high risk of developing CFRD and a lower probability of weight gain in both adults and children with CF....

Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.

Epidermolytic palmoplantar keratoderma (EPPK), a highly penetrant autosomal dominant genodermatosis, is characterized by diffuse keratoses on palmplantar epidermis. The keratin 9 gene (KRT9) is respon...

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at XXX between 2005 and 2015. During a minimum 12-month post-therapy follow-up period, 173 patient... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned by the soft-margin SVM into distinct regions with differen... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool for ORN (ba...

Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis.

This study aimed to elucidate the therapeutic effects of Huaier granules on hepatocellular carcinoma (HCC) within the Milan criteria in patients who underwent microwave ablation (MWA).... A total of 228 patients were included, with 97 in the Huaier group and 131 in the control group. We evaluated progression-free survival (PFS), overall survival (OS), and extrahepatic metastasis surviv... Following PSM, the 1-, 3-, and 5-year PFS rates in the Huaier and control groups were 83.5% vs 70.7%, 57.7% vs 42.6%, and 43.6% vs 31.9% (... Huaier granules can reduce the risk of recurrence and improve the OS of patients with HCC within the Milan criteria following MWA. Administering Huaier granules for over 6 months proved beneficial....

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at the University of Texas MD Anderson Cancer Center between 2005 and 2015. The (structural) clust... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned almost perfectly by the soft-margin SVM into distinct regi... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool (based on t...

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).

The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiati... To emulate a target trial to evaluate the cognitive outcomes of initiating an ARB- vs ACEI-based antihypertensive regimen in individuals at risk for mild cognitive impairment (MCI) and probable dement... Active comparator, new-user observational cohort study design using data from the Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018. Marginal cause-specifi... New users of ARB vs ACEI during the first 12 months of trial follow-up.... Composite of adjudicated amnestic MCI or PD.... Of 9361 participants, 727 and 1313 new users of an ARB or ACEI, respectively, with well-balanced baseline characteristics between medication exposure groups after inverse probability weighting (mean [... In this observational cohort study of US adults at high cardiovascular disease risk, there was no difference in the rate of amnestic MCI or PD among new users of an ARB compared with ACEI, although 95...